<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">scbmt</journal-id><journal-title-group><journal-title xml:lang="ru">БИОМЕДИЦИНА</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Biomed</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-5982</issn><issn pub-type="epub">2713-0428</issn><publisher><publisher-name>Scientific center of biomedical technologies of Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33647/2074-5982-20-3-75-79</article-id><article-id custom-type="elpub" pub-id-type="custom">scbmt-1608</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ В БИОМЕДИЦИНЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NON-CLINICAL RESEARCH IN BIOMEDICINE</subject></subj-group></article-categories><title-group><article-title>Оценка эффективности двойной комбинированной терапии экспериментальной хронической сердечной недостаточности</article-title><trans-title-group xml:lang="en"><trans-title>Efficacy Assessment of Dual Combined Therapy in Experimental Chronic Heart Failure</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивкин</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivkin</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ивкин Дмитрий Юрьевич, к.б.н., доц.</p><p>197376, Санкт-Петербург, ул. Профессора Попова, 14, лит. А</p></bio><bio xml:lang="en"><p>Dmitry Yu. Ivkin, Cand. Sci. (Biol.), Assoc. Prof.</p><p>197376, Saint Petersburg, Professora Popova Str., 14, lit. A</p></bio><email xlink:type="simple">dmitry.ivkin@pharminnotech.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Краснова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasnova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснова Марина Викторовна</p><p>197376, Санкт-Петербург, ул. Профессора Попова, 14, лит. А</p></bio><bio xml:lang="en"><p>Marina V. Krasnova</p><p>197376, Saint Petersburg, Professora Popova Str., 14, lit. A</p></bio><email xlink:type="simple">marina.krasnova@pharminnotech.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карпов Андрей Александрович, к.м.н.</p><p>197376, Санкт-Петербург, ул. Профессора Попова, 14, лит. А</p></bio><bio xml:lang="en"><p>Andrew A. Karpov, Cand. Sci. (Med.)</p><p>197376, Saint Petersburg, Professora Popova Str., 14, lit. A</p></bio><email xlink:type="simple">a--karpoff@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Оковитый</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Okovitiy</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оковитый Сергей Владимирович, д.м.н., проф.</p><p>197376, Санкт-Петербург, ул. Профессора Попова, 14, лит. А</p></bio><bio xml:lang="en"><p>Sergey V. Okovitiy, Dr. Sci. (Med.), Prof.</p><p>197376, Saint Petersburg, Professora Popova Str., 14, lit. A</p></bio><email xlink:type="simple">sergey.okovity@pharminnotech.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куликов</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulikov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куликов Александр Николаевич, д.м.н., проф.</p><p>197022, Санкт-Петербург, ул. Льва Толстого, 6–8</p></bio><bio xml:lang="en"><p>Alexander N. Kulikov, Dr. Sci. (Med.), Prof.</p><p>197022, Saint Petersburg, L’va Tolstogo Str., 6–8</p></bio><email xlink:type="simple">ankulikov2005@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет  им. академика И.П. Павлова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Saint Petersburg State Medical University named after Academician I.P. Pavlov  of the Ministry of Health Care of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2024</year></pub-date><volume>20</volume><issue>3</issue><fpage>75</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ивкин Д.Ю., Краснова М.В., Карпов А.А., Оковитый С.В., Куликов А.Н., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ивкин Д.Ю., Краснова М.В., Карпов А.А., Оковитый С.В., Куликов А.Н.</copyright-holder><copyright-holder xml:lang="en">Ivkin D.Y., Krasnova M.V., Karpov A.A., Okovitiy S.V., Kulikov A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.scbmt.ru/jour/article/view/1608">https://journal.scbmt.ru/jour/article/view/1608</self-uri><abstract><p>Представлены результаты экспериментальных исследований эффективности двойных комбинаций традиционных средств базисной терапии хронической сердечной недостаточности с эмпаглифлозином при моделировании патологии у лабораторных аутбредных крыс. В рамках исследования проводилась оценка выживаемости, физической выносливости, эхокардиографических показателей. Наиболее эффективной оказалась комбинация эмпаглифлозина с фозиноприлом: шестимесячная выживаемость составила 90%, наблюдалась наибольшая толерантность к физической нагрузке (50% прирост по отношению к животным группы патологии без лечения), фракции укорочения и выброса возрастали на 25%. </p></abstract><trans-abstract xml:lang="en"><p>The article presents the results of experimental studies into the efficacy of dual combinations of conventional drugs for the basic treatment of chronic heart failure with empagliflozin when modeling the pathology in laboratory outbred rats. As part of the study, survival, physical tolerance, and echocardiographic parameters were assessed. The most effective combination was found to be the therapy by empagliflozin with fosinopril. In this case, the six-month survival rate achieved 90%; a greater tolerance to physical activity was observed (50% increase in relation to animals in the pathology group without treatment); shortening and  ejection fractions increased by 25%.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тредмил</kwd><kwd>фозиноприл</kwd><kwd>бисопролол</kwd><kwd>спиронолактон</kwd></kwd-group><kwd-group xml:lang="en"><kwd>treadmill</kwd><kwd>fosinopril</kwd><kwd>bisoprolol</kwd><kwd>spironolactone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Карпов А.А., Ивкин Д.Ю., Драчева А.В., Питухина Н.Н., Успенская Ю.К., Ваулина Д.Д., Усков И.С., Эйвазова Ш.Д., Минасян С.М., Власов Т.Д., Бурякина А.В., Галагудза М.М. Моделирование постинфарктной сердечной недостаточности путём окклюзии левой коронарной артерии у крыс: техника и методы морфофункциональной оценки. Биомедицина. 2014;3:32–48.</mixed-citation><mixed-citation xml:lang="en">[Karpov A.A., Ivkin D.Yu., Dracheva A.V., Pitukhina N.N., Uspenskaya Yu.K., Vaulina D.D., Uskov I.S., Eyvazova Sh.D., Minasyan S.M., Vlasov T.D., Buryakina A.V., Galagudza M.M. Modelirovanie postinfarktnoy serdechnoy nedostatochnosti putem okklyuzii levoy koronarnoy arterii u krys: tekhnika i metody morfofunktsional'noy otsenki [Rat model of post-infarct heart failure by left coronary artery occlusion: Technical aspects, functional and morphological assessment]. Biomeditsina [Journal Biomed]. 2014;3:32–48. (In Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Krasnova M., Kulikov A., Okovityi S., Ivkin D., Karpov A., Kaschina E., Smirnov A. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Naunyn Schmiedebergs Arch. Pharmacol. 2020;393(9):1649–1658. DOI: 10.1007/s00210-020-01873-7</mixed-citation><mixed-citation xml:lang="en">Krasnova M., Kulikov A., Okovityi S., Ivkin D., Karpov A., Kaschina E., Smirnov A. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Naunyn Schmiedebergs Arch. Pharmacol. 2020;393(9):1649–1658. DOI: 10.1007/s00210-020-01873-7</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
